Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity
Executive Summary
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
You may also be interested in...
Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression
Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.
Pfizer's COVID-19 Vaccine Commercialization Plan Includes DTC Campaign
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports